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Abstract
Summary We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to
short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the
highest risk of fracture. These patients should be monitored for fracture management strategies.
Purpose The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture risk remains debated. We
therefore aimed to examine the hip fracture risk associated with short courses and heavy use of high-dosed oral glucocorticoids.
Methods We conducted a population-based case-control study using the Danish National Health Service data, 1996–2011. Cases
were those aged ≥ 18 years who sustained a hip (primary outcome) fracture (n = 81,342). Vertebral and forearm fractures were
considered in secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily dose (DD) and total
cumulative dose (CD) were calculated among current oral glucocorticoid users. Among patients with a high daily dose (DD ≥
15mg), we identified short-course users as those with a CD< 1 g and heavy users as those with a CD ≥ 1 g.We estimated adjusted
odds ratio (adj.OR) of fracture with current glucocorticoid use compared to never-use, using conditional logistic regression.
Results A high DD (≥ 15mg) and high CD (≥ 1 g) were independently associated with an increased hip fracture risk (adj.OR 2.5;
95% CI 2.2–2.9; adj.OR 1.6; 95% CI 1.5–1.8, respectively). However, the risk was substantially increased among heavy users
(DD ≥ 15 mg and CD ≥ 1 g: adj.OR 2.9; 95% CI 2.5–3.4) as compared to short-course users (DD ≥ 15 mg and CD < 1 g: adj.OR
1.4; 95% CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little association was identified for forearm fractures.
Conclusion Among patients receiving a high DD (≥ 15 mg), heavy users (≥ 1 g CD) showed the most substantial increase in hip
fracture risk. Among those receiving high DD, a threshold of 1 g CD may identify heavy users that are candidates for focused
fracture management services.
Keywords Oral glucocorticoids . Osteoporosis . Hip fracture . Case-control
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s11657-018-0424-x) contains supplementary
material, which is available to authorized users.
* Andrea M. Burden
Andrea.burden@mumc.nl
1 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,
Canada
2 Department of Clinical Pharmacy and Toxicology, Maastricht
University Medical Centre+, Maastricht, The Netherlands
3 Care and Public Health Research Institute (CAPHRI),
Maastricht, The Netherlands
4 Division of Pharmacoepidemiology and Clinical Pharmacology,
Utrecht Institute of Pharmaceutical Sciences, Utrecht University,
Utrecht, The Netherlands
5 NUTRIM School for Nutrition and Translational Research in
Metabolism, Maastricht University, Maastricht, The Netherlands
6 Department of Clinical Medicine, Aalborg University,
Aalborg, Denmark
7 Department of Endocrinology, Aalborg University Hospital,
Aalborg, Denmark








Oral glucocorticoids are widely prescribed drugs with
established clinical benefits for patients with chronic inflam-
matory and autoimmune diseases, such as chronic respiratory
disease, inflammatory arthritis, and dermatologic disease
[1–3]. It is estimated that the prevalence of oral glucocorticoid
use among adults ranges between 1.5 and 3% worldwide [4].
Unfortunately, oral glucocorticoid use is limited by significant
side effects that usually appear after an extended period of
exposure [5–7]. Glucocorticoid-induced musculoskeletal dis-
orders, such as osteoporosis, are a major problem and a well-
documented side effect [8–13]. Indeed, it is estimated that oral
glucocorticoids are associated with a 30 to 120% increased
risk of hip fracture and 2- to 3-fold increase in vertebral frac-
ture risk compared with non-use [14–16]. For inflammatory
conditions, short courses of high doses with tapering regimens
are often required for symptom management. While it is well-
known that oral glucocorticoid-induced bone loss and fracture
risk is dose-dependent [15, 17], the relationship with the cu-
mulative exposure is less well established [15, 17].
To minimize fracture risk, clinical practice guidelines rec-
ommend that osteoporosis pharmacotherapy should be given
to patients that are expected to receive a daily dose of 5 to
7.5 mg of prednisone equivalent for 3–6 months [10, 18–20].
However, in a real-world setting, patients with inflammatory
conditions often receive intermittent short courses (7–14 days)
of high doses (40–60 mg per day), or a continuous low dose
(5–10 mg per day) for longer periods until remission of the
underlying disease [21–23]. In both cases, this may result in a
similar cumulative exposure; however, the impact on bone
and fracture may differ due to the daily dose.
To date, data related to the risk of bone fracture associated
with these different patterns of exposure are limited, and it is
often difficult to examine different cumulative and daily dose
exposure patterns in database research. Thus, in this study
using population-level data from Denmark, we sought to ex-
amine the association between the daily dose and cumulative
exposure to oral glucocorticoids and the risk of fracture. Hip
fracture is the most burdensome osteoporotic fracture, and its
identification using hospital and physician diagnosis codes is
accurate compared to other common osteoporosis fractures
[24, 25]. In particular, we focus on the effect of Bshort
courses^ or Bheavy use^ of high daily doses of oral glucocor-
ticoids and hip fracture risk. Additionally, as the association of
oral glucocorticoid exposure with other fractures (forearm and
vertebra) is not yet clear, we further examined other fracture
sites in secondary analyses.
Methods
Data sources
We utilized data from the Danish National Health Service
Register that covers all contacts with the health sector for over
five million individuals in Denmark [26]. The National Health
Service Register captures all contacts with general practi-
tioners. The National Hospital Discharge Register includes
information on hospital admissions since 1977 and all outpa-
tient and emergency department visits since 1995 [27]. All
diagnoses are coded using the International Classification of
Diseases and Related Health Problems (ICD) system, with
high precision for diagnoses, particularly for fractures [28].
The vital status for the entire Danish population is identified
from the Civil Registration System. The Danish Medicines
Agency Register of Medicinal Product Statistics is a nation-
wide prescription database that uses the Anatomical
Therapeutic Chemical Classification (ATC) system and in-
cludes information on the type, amount, and prescription date.
All registers can be linked at the patient level using the unique
10-digit civil registry number assigned to all Danish citizens
[29].
Study design
We completed a population-based case-control study. Cases
were all patients aged 18 years or older, who sustained the first
ever hip, vertebral, or forearm fracture between January 1,
1996, and December 31, 2011. The primary fracture of interest
was hip fracture (ICD-10 codes: S72.0–S72.2). We further
identified patients with clinical symptomatic vertebral frac-
tures (ICD-10 codes: S12, S22.0, S22.1, S32.0, T08) and
forearm fractures: radius or ulna (ICD-10 code: S52).
We randomly selected a control for each case, matched on
age and year of birth, using incidence density sampling.
Controls had no fracture during the study period. The date of
the first fracture was used as the index date for the cases, and
controls were assigned the index date of their matched case.
Exposure
We defined oral glucocorticoid exposure based on most recent
glucocorticoid prescription prior to the index date: current
(within 91 days), recent (92–182 days), past (183–364 days),
and distant past (≥ 365 days). Patients with no glucocorticoid
prescriptions prior to the index date were classified as never
users and were the referent category in all analyses.
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Average daily dose (DD) and the cumulative dose (CD) of
oral glucocorticoids were calculated among current users and
expressed as prednisone equivalents. The average DD was
calculated by dividing CD by the treatment time (days be-
tween the first glucocorticoid prescription to the index date),
and categorized into three groups: low (< 7.5 mg), moderate
(7.5–14.9 mg), and high (≥ 15 mg). CD was calculated by
summing defined daily doses of glucocorticoid prescriptions
prior to the index date, according to the World Health
Organization. The primary exposure categories of interest
were defined as follows: CD was categorized as low (< 1 g
CD) or high (≥ 1 g CD) (Fig. 1). In a secondary analysis, we
defined high CD as ≥ 5 or ≥ 10 g, with relevant sub-groups of
CD (1.0–4.9 g, and 5.0–9.9 g), where appropriate.
To examine fracture risk associated with different patterns
of glucocorticoid exposure, we further stratified exposure by
both DD and CD to capture short-course and heavy users of
highDD (≥ 15mg) oral glucocorticoids. Among these patients
with a high DD, we defined Bshort-course users^ as those with
< 1 g CD, while Bheavy users^ were those with a CD ≥ 1 g.
These definitions were used as a heavy user would be a patient
receiving 2–3 months of 15 mg daily, or more than a 30-day
exposure to 40–60 mg daily.
Covariates
A history of the following comorbidities were identified if
they occurred any time before a patient’s index date: second-
ary osteoporosis (diabetes type 1, hypogonadism, or prema-
ture menopause), fracture (prior to 1996), rheumatoid arthritis,
gout, inflammatory bowel disease, chronic obstructive pulmo-
nary disease, alcoholism, cerebrovascular disease, congestive
heart failure, pneumonia, type 2 diabetes mellitus, hyperthy-
roidism, hypothyroidism, malignancies (excluding non-
melanoma skin cancer), dementia, and retinopathy. All poten-
tial confounders were identified using ICD-8 or ICD-10
codes. In the 6 months before the index date, we identified
the following prescriptions as potential confounders: bone-
sparing drugs (bisphosphonates, vitamin D, calcium, calcito-
nin, denosumab, raloxifene, and strontium ranelate), hormone
replacement therapy, parathyroid hormone, antidepressants,
antipsychotics, hypnotics/anxiolytics, anticonvulsants, anti-
Parkinson drugs, inhaled bronchodilators, inhaled corticoste-
roids, xanthine derivatives, antihypertensive drugs, and proton
pump inhibitors.
Statistical analysis
Conditional logistic regression was used to estimate the asso-
ciation between the use of oral glucocorticoids and fracture
risk. All results are presented as odds ratios (ORs) with the
corresponding 95% confidence intervals (95% CIs). Analyses
were stratified by DD, CD, and the DD stratified by CD (i.e.,
short-course vs. heavy use). Final regression models were
determined using stepwise backward elimination using a sig-
nificance level of 0.05. We completed an additional analysis
that adjusted the final model for osteoporosis medications in
addition to identified significant covariates. Separate models
were run for hip (primary outcome), clinical symptomatic ver-
tebral, and forearm fracture. Analyses were conducted using
SAS software version 9.3 (SAS Institute Inc., Cary, NC).
Results
Primary fracture site: hip fracture
We identified 81,342 cases of hip fracture who were well
matched to controls on age (mean 78.6 years, standard devia-
tion 12 years) and sex (women 68.5%) (Table 1). Compared
with controls, a higher proportion of cases had comorbidities,
such as the history of fracture (27 cases vs. 11% controls),
chronic obstructive pulmonary disease (10 cases vs. 7% con-
trols), and secondary osteoporosis (8 cases vs. 5% controls).
Drug use in the 6 months prior to the index date was higher
among the fracture cases, as compared to controls:
bisphosphonates (3.5 vs. 2.4%), antipsychotics (9.3 vs.
4.3%), anticonvulsants (4.5 vs. 1.9%), and antidepressants




Distant past use Past use Recent use Current use
(> 365 days) (183-364 days) (182-92 days) (<92 days)
Exposure assessment* 
DD: <7.5 - 7.5-15 - ≥15 mg
CD: < 1g - ≥1g
Comorbidities 
Drug use (182-0 days)
Fig. 1 Study design diagram. *DD: average daily dose in milligrams of
prednisone equivalent measured among current users. *CD: cumulative
exposure in grams of prednisone equivalent measured among current
users. Notes: index date: defined as the first fracture occurring between
1996 and 2011. Oral glucocorticoid exposure based on most recent
glucocorticoid prescription prior to the index date: current (within
91 days), recent (92–182 days), past (183–364 days), and distant past
(> 364 days). Comorbidities: any diagnoses code prior to the index
date. Drug use: any drug prescription within 6 months prior to the
index date. Previous fracture: any fracture prior to January 1996
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A total of 16,606 patients with hip fracture (20.4%) and
13,763 controls (17.0%) had used oral glucocorticoids prior to
the index fracture (Supplementary material, Table 1). Current
use of oral glucocorticoids was associated with an increased
risk of hip fracture (adjusted [adj] OR 1.56, 95% CI [1.48–
1.65]), as compared to never users of oral glucocorticoids
(Fig. 2). Among current users, a dose-response relationship
was observed with increasing DD: < 7.5 mg (adj.OR 1.37
[95% CI 1.23–1.47]), 7.5–14.9 mg (adj.OR 1.53 [95% CI
1.39–1.68]), and ≥ 15 mg (adj.OR 2.5 [95% CI 2.19–2.85])
(Appendix Table 1a). Likewise, a higher CD was associated
with an increased hip fracture risk. A CD < 1 g was associated
with a 30% increased hip fracture risk (adj.OR 1.28 [95% CI
1.14–1.44]), while a 60% increased risk was observed for CD
≥ 1 g (adj.OR 1.64 [95% CI 1.54–1.74]), CD ≥ 5 g (adj. OR
1.61 [95% CI 1.50–1.74]), and CD ≥ 10 g (adj.OR 1.57 [95%
CI 1.42–1.73]).
To examine the association between Bheavy^ and Bshort-
course^ users of high-dosed oral glucocorticoids, the DD was
further stratified by the CD (Fig. 2). Among short-course users
(DD ≥ 15 mg and CD < 1 g), a 42% increase in hip fracture
risk was observed (adj.OR 1.42 [95% CI 1.08–1.86]). In con-
trast, Bheavy^ use of high doses (DD ≥ 15 mg and CD ≥ 1 g)
resulted in a tripled risk of hip fracture (adj.OR 2.94 [95% CI
2.52–3.42]). When CD exceeded 5 or 10 g, among those with
a high DD, the hip fracture risk was similar (CD ≥ 5 g: adj.OR
Table 1 Baseline characteristics
of cases of hip fracture and
controls
Cases (n = 81,342) Controls (n = 81,342)
Characteristics N % n % p value
Women 55,776 68.6 55,776 68.6 1
Mean age in years (SD) 78.6 (12.0) 78.6 (12.0) 0.99
Age group
18–49 years 2237 2.8 2240 2.8 0.99
50–59 years 3791 4.7 3794 4.7 0.99
60–69 years 8565 10.5 8578 10.6 0.91
70–79 years 21,513 26.5 21,545 26.5 0.86
80+ years 45,236 55.6 45,185 55.6 0.8
History of comorbidities
Chronic obstructive pulmonary disease 7986 9.8 5293 6.5 < 0.001
Fracture (prior to 1996) 21,653 26.6 8672 10.7 < 0.001
Rheumatoid arthritis 2318 2.9 1452 1.8 < 0.001
Inflammatory bowel disease 1998 2.5 1405 1.7 < 0.001
Secondary osteoporosisa 6189 7.6 3951 4.9 < 0.001
Drug use 6 months before index date
Bisphosphonates 2868 3.5 1917 2.4 < 0.001
Vitamin D 156 0.2 122 0.2 < 0.05
Calcium 1718 2.1 1109 1.4 < 0.001
Raloxifene 104 0.1 62 0.1 < 0.01
Strontium ranelate 37 0.1 19 0.0 0.01
Denosumab 8 0.0 – – –
Parathyroid hormone 30 0.0 20 0.0 0.16
Hormone replacement therapy 4306 5.3 5875 7.2 < 0.001
Inhaled corticosteroids 2948 3.6 2625 3.2 < 0.001
Inhaled bronchodilators 7020 8.6 5436 6.7 < 0.001
Antipsychotics 7552 9.3 3496 4.3 < 0.001
Antidepressants 18,138 22.3 8783 10.8 < 0.001
Hypnotics/anxiolytics 13,053 16.1 8734 10.7 < 0.001
Anticonvulsants 3660 4.5 1539 1.9 < 0.001
Anti-Parkinsonian drugs 2124 2.6 841 1.0 < 0.001
Comorbidities: any diagnoses code (ICD-8 or ICD-10) recorded prior to the index date. Drug use: any drug
prescription within 6 months prior to the index date. Cells < 6 are not reported
SD standard deviation
a Secondary osteoporosis defined as a diagnosis of diabetes type 1, hypogonadism, or premature menopause
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Fig. 2 Odds ratio of hip fracture
by glucocorticoid use (vs. never)
[GC, glucocorticoid, DD (average
daily dose), CD (cumulative
dose)]. Oral glucocorticoid
exposure based on most recent
glucocorticoid prescription prior
to the index date: current (within
91 days), recent (92–182 days),
past (183–364 days), and distant
past (> 364 days). DD and CD
were calculated among current
users. Adjusted for history of
chronic obstructive pulmonary






sparing drugs, and inhaled
bronchodilators
Fig. 3 Odds ratio of vertebral
fracture by glucocorticoid dose
(vs. never) [GC, glucocorticoid,
DD (average daily dose), CD
(cumulative dose)]. Oral
glucocorticoid exposure based on
most recent glucocorticoid
prescription prior to the index
date: current (within 91 days),
recent (92–182 days), past (183–
364 days), and distant past (>
364 days). DD and CD were
calculated among current users.
Adjusted for history of chronic
obstructive pulmonary disease,






sparing drugs, and inhaled
bronchodilators
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2.86 [95% CI 2.29–3.58] and CD ≥ 10 g: adj.OR 2.55 [95%
CI 1.84–3.55]).
Secondary fracture sites: vertebral and forearm
fractures
Figure 3 and Appendix Table 2 present the ORs of clinical
symptomatic vertebral fracture by glucocorticoid exposure.
Current use of oral glucocorticoids was associated with dou-
bled risk of clinical symptomatic fracture (adj. OR 2.36 [95%
CI 2.15–2.60]). A highDD (≥ 15mg/day) was associated with
a 3.8-fold increased clinical vertebral fracture risk (adj.OR
3.76 [95%CI 2.97–4.77]), and a CD ≥ 1 g was associated with
a tripled risk (adj.OR 2.96 [95% CI 2.40–3.65]). Among the
high DD users, short-course use was associated with a dou-
bled risk of clinical symptomatic vertebral fracture risk
(adj.OR 2.13, 95% CI 1.30–3.49), while Bheavy^ use was
associated with a more than 4-fold increased risk (adj.OR
4.36, 95% CI 3.32–5.72) (Fig. 3 and Appendix Table 2).
Among patients with forearm fractures, the analysis
showed minimal to no association with oral glucocorticoid
exposure (Fig. 4). No dose-response of forearm fracture risk
was observed (Fig. 4 and Appendix Table 3).
Discussion
In this population-based case-control study, we identified that
heavy use (high DD and high CD) of oral glucocorticoids was
associated with a 3-fold increased hip fracture risk, which was
substantially higher as compared to short-course users. While
both the DD and CD were independently associated with hip
fracture risk, our results suggest that hip fracture risk was
modified by the CD among patients receiving a high DD of
oral glucocorticoids. This association was not observed
among patients with a low to moderate DD, thereby suggest-
ing that heavy users of high DD oral glucocorticoids are a
distinct patient group with substantially elevated fracture risk.
Interestingly, in our study, we did not observe an incremen-
tal increase in hip fracture risk among patients receiving CD
exceeding 1 g of prednisone equivalent (≥ 5 or ≥ 10 g). This
result may indicate a threshold effect for the CD, which may
be used to guide clinical decision making to determine pa-
tients in need of fracture/osteoporosis management. Our study
further showed that the odds of sustaining fractures among
glucocorticoid users were stronger for clinical symptomatic
vertebral fracture than hip fracture, while forearm fracture risk
was minimal to non-significant among current users and
across dose categories.
Systemic glucocorticoids cause considerable inhibition of
bone formation and bone resorption, but particularly when
given at higher doses and longer durations. Additionally, sys-
temic glucocorticoids impair renal and intestinal calcium ab-
sorption, reduce sexual hormone secretion, and cause muscle
atrophy and gait impairment, which in turn increase bone loss
and fracture risk [5]. These pleiotropic effects significantly
increase fracture risk, and we speculate that it is the high daily
and cumulative doses which can explain the effect modifica-
tion that we observed. Our finding is also in line with a pre-
vious cohort study in the UK [15].
In clinical practice, treatment with bisphosphonates for os-
teoporosis management is often suboptimal among patients
Fig. 4 Odds ratio of forearm fracture by glucocorticoid use (vs. never)
[GC, glucocorticoid, DD (average daily dose), CD (cumulative dose)].
Oral glucocorticoid exposure based on most recent glucocorticoid
prescription prior to the index date: current (within 91 days), recent
(92–182 days), past (183–364 days), and distant past (> 364 days). DD
and CD were calculated among current users. Adjusted for history of
chronic obstructive pulmonary disease, fracture (prior to 1996),
rheumatoid arthritis, inflammatory bowel disease, secondary
osteoporosis, antidepressants, anxiolytics and hypnotics, anticonvulsants
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receiving oral glucocorticoids, particularly those receiving
short courses as they do not reach the guideline recommenda-
tion of 7.5 mg per day for a duration of 3 months. As a result,
these patients remain at high risk for potentially devastating
hip fractures. Since the cycle of bone remodeling takes on
average 3 months [30], multiple short courses are likely to
hinder bone metabolism by preventing the skeleton to
completely regenerate. Indeed, data have shown that fracture
risk can persist up to 1 year after oral glucocorticoid cessation
[15, 17]. However, the association between a more intermit-
tent exposure to high DD and fracture remains controversial.
Moreover, the effect of a CD of oral glucocorticoids, particu-
larly in relation to the DD, on fracture risk remains debated.
While it is well established that a DD exceeding 15 mg is
associatedwith a significant increase in fracture risk, our study
highlighted that the magnitude of fracture risk associated with
a high DD differed depending on the CD thresholds. We ob-
served that patients receiving short courses (< 1 g CD) of high
DD had an elevated hip and clinical symptomatic vertebral
fracture risk, yet heavy users (≥ 1 g CD) of high DD had a
tripled risk of hip fracture, and a 4.5-fold increase in clinical
symptomatic vertebral fracture risk. Interestingly, we ob-
served that fracture risk reached a plateau starting at a CD ≥
1 g. Prior studies have shown that glucocorticoid daily dose is
a stronger predictor than the cumulative dose [12, 15, 16].
However, our results suggest that high DD with low CD does
not confer higher risk of fractures, and therefore, we assume
that there is a threshold duration of exposure or a minimum
number of high daily doses that are causing the highest risk of
fracture. Our results support that a clinical threshold of 1 g
prednisone equivalent may be useful to guide therapeutic in-
terventions to prevent osteoporotic fracture. Indeed, clinical
practice guidelines use various oral glucocorticoid exposure
thresholds to consider anti-fracture treatment, yet no agree-
ment between guidelines is established [10, 18–20].
When placing our results in the context of the literature, we
note that the most comparable study to ours is a large cohort
study conducted by de Vries et al., using the UK primary care
data (Clinical Practice Research Datalink) to examine fracture
risk among glucocorticoid users covering the period between
1987 and 1997 [15]. In their study, de Vries et al. examined
similar glucocorticoid DD and CD exposure to our study, and
showed a 49% increase in relative risk of hip and femur frac-
ture, and more than 3-fold risk increase of vertebral fracture.
The authors showed similar dose-response patterns for the
average DD and CD and osteoporotic fracture overall.
However, contrary to our study, de Vries et al. assessed frac-
ture risk by disease at baseline, limiting the direct comparison
with our study. Additionally, the comparator group in the
study by de Vries et al. were those with past use of glucocor-
ticoids, while never users were compared in our study. Thus, a
larger overall effect of current use in our study would be
expected.
Additionally, a case-control study in the Netherlands inves-
tigated inhaled and oral glucocorticoid users from 1991 to
2002, identifying cases of 366 hip or femur fracture among
current oral glucocorticoid users [31]. This study examined
daily dose-response and showed lower overall risk than iden-
tified in our study. However, this study did not consider the
total CD of glucocorticoids, which is an important factor to
estimate differential fracture risk. Consequently, we are unable
to make a direct comparison regarding the effect of heavy or
short-term use on fracture risk. Finally, Vestergaard et al.
showed that the highest increase in hip fracture risk by cumu-
lative dose was among patients receiving ≥ 1500 mg predni-
sone equivalent in the year preceding the fracture (OR 4.2
95% CI [1.96–9.00] vs. OR 1.89[1.62–2.21] for patients re-
ceiving 500–1499 mg prednisone equivalent) [32]. However,
this analysis was not stratified by glucocorticoid daily dose.
Other observational studies have examined the association
of short courses of glucocorticoid exposure and support our
findings of a moderately increased fracture risk. A cohort
study using administrative healthcare databases reported a
similar increase in hip fracture risk (60%) among all glucocor-
ticoid users, and RR of hip fracture equal to 1.26 (95% CI
0.87–1.83) among patients with short courses of oral gluco-
corticoids (< 90 days). A lack of statistical power is likely to
cause the non-significant results for short courses. Another
cohort study reported increased risk of hip fracture among oral
glucocorticoid users (RR 1.87, 95% CI 1.19–2.94) [16]. In
addition, increase in daily dose and duration were significant-
ly associated with hip and clinical symptomatic vertebral frac-
ture risk. This study showed that short duration of oral gluco-
corticoid exposure also increased fracture risk.
In interpreting our data, we are mindful of some limitations.
By design, the case-control study is not able to provide an
absolute risk. We used a density sampling technique which
allowed us to interpret the odds ratio as risk ratio since con-
trols were selected based on the person-time duration corre-
sponding to each case [33]. There remains debate of the
thresholds of glucocorticoid exposure resulting in fracture
risk. Consequently, our definition of dose and duration thresh-
olds may be debatable. Many guidelines recommend treat-
ment among patients receiving a planned systemic glucocor-
ticoid dose ≥ 7.5 mg prednisone equivalent daily and a dura-
tion of 3 months [19, 34]. However, the patterns of glucocor-
ticoid exposure are often complex, requiring multiple courses
and may therefore not meet guidelines for treatment, leaving
many patients at risk. While the definition of high glucocorti-
coid daily doses is debated, doses < 7.5 mg/day prednisone
equivalent are often considered as low doses in clinical trials
of oral glucocorticoids [35, 36]. While our study did not iden-
tify significant differentiation between those receiving <
7.5 mg daily and those receiving 7.5–14.9 mg daily, there
was a significant increased hip and vertebral fracture risk
among those receiving ≥ 15 mg daily.
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Additionally, there may be limitations regarding our defi-
nition of short-course and heavy users of high DD oral gluco-
corticoids. In this study, we assumed patients with a DD ≥
15 mg and CD < 1 g may have received intermittent use
(short-courses) of oral glucocorticoid therapy, as this would
suggest that a patient received two or fewer 30-day courses of
15 mg per day. Conversely, the heavy users with ≥ 1 g CD
weremore likely to have receivedmore prolonged exposure to
oral glucocorticoid therapy. Using a combination of CD and
DD to describe patterns of exposure may not be the most
optimal choice. In many clinical cases, dosing schedule of oral
glucocorticoids consists of a high DD and a short duration. In
this study, we assumed that less than 1 g of prednisone equiv-
alent before the fracture event is indicative of short-course or
intermittent use for acute symptom management. This would
correspond to one or two 30-day courses of 15 mg per day.
However, it is possible that intermittent users may accumulate
more than 1 g of exposure if a DD exceeded 30 mg.
Nonetheless, we expect that this is likely to happen in very
few cases only.
Additionally, while we adjusted for common glucocorti-
coid indications, we did not stratify our results by the specific
disease indications. Similarly, while we adjusted comorbidi-
ties and drug use, residual confounding remains a limitation.
We recognize that other risk factors have not been captured in
our data and therefore not adjusted for. These include patient
body mass index, smoking status, and bone mineral density
values. However, we note that de Vries et al. reported similar
results using UK data, which adjusted for these variables, and
there is evidence showing that the fracture risk could be partly
independent from the diminished bone density in patients who
take oral glucocorticoids [37].
Another limitation was the possibility of misclassification
bias in the Danish database. Vertebral fractures can be asymp-
tomatic and likely have a low predictive value when defined
using claims data [38]. This may have resulted in an
underestimated effect in our vertebral fracture results.
However, we believe there is little chance of differential mis-
classification and commonly used codes for osteoporotic frac-
ture were identified. Additionally, misclassification of expo-
sure is possible with glucocorticoids as information was de-
rived from pharmacy claims, and we cannot be assured that
the pills were taken as prescribed. Indeed, glucocorticoids
may be prescribed on a Btake-as-needed^ basis, and therefore
may have been collected at the pharmacy and not taken. In this
study, the average daily dose was used, yet we acknowledge
that this method has limitations with oral glucocorticoids, par-
ticularly when the glucocorticoid regimen requires adjustment
and gradual tapering for long exposure periods [39]. This may
result in underestimating the DD. However, the CD may par-
tially adjust for this by estimating the overall exposure.
There are several strengths to our current study. We used
the Danish nationwide population register, which is a large
population-based register that permitted the examination of a
large number of cases and controls. In Denmark, all residents
receive universal medical and prescription services. Thus, the
data are complete and collected longitudinally. This data also
permitted the inclusion of many important confounders.
Additionally, the prescription data in Denmark are claims-
based and collected longitudinally, permitting us to calculate
a reliable cumulative and average daily dose. Moreover, all
data on fractures have been validated [40], minimizing the
effect of misclassification.
Clinical implication
The literature is consistent with respect to increases in fracture
risk related to oral glucocorticoid exposure, yet the indepen-
dent and combined effects of DD and CD on fracture risk
remains controversial. According to the underlying condition,
patients are faced with various instructions regarding gluco-
corticoid exposure—including tapering over time, alternate-
day use, and Btake as needed^ instructions. Thus, defining an
exposure threshold to initiate osteoporosis treatment is ambig-
uous, and difficult to assess in research using population-
based data. In general, the literature shows suboptimal osteo-
porosis management among oral glucocorticoid users, where
up to 70% of eligible users have no bone protection treatment
[3, 41]. Many oral glucocorticoid users may not fall under
clinical guidelines’ eligibility criteria to receive osteoporosis
management.
The results of this study, therefore, provide additional evi-
dence that a high DD (≥ 15mg/day) and a CD exceeding 1 g is
likely to cause the greatest risk of hip and clinical symptom-
atic vertebral fracture. Thus, while patients receiving short
courses of high DD should continue to be monitored, focused
attention for fracture management and osteoporosis pharma-
cotherapy should be given to patients with heavy use. These
results may help clinical guidance to elaborate an evidence-
based strategy for bone protection among oral glucocorticoid
users.
Conclusion
In conclusion, heavy use of high-dosed oral glucocorticoids is
associated with a substantial 3-fold increase in hip fracture
risk. Therefore, while short courses or more intermittent use
of high-dosed oral glucocorticoids do increase fracture risk,
primary attention should be paid to patients with heavy use—
defined as those receiving multiple short or prolonged courses
of high glucocorticoid doses that result in a cumulative expo-
sure exceeding 1 g prednisone equivalent. Knowing a pa-
tients’ prescription history to identify the cumulative exposure
to high daily doses of oral glucocorticoids may help clinicians
to identify patients that are at high risk of fractures. These
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patients should then be targeted for osteoporosis management
strategies to minimize fracture risk.
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